Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B06AC01

Cinryze(C1 inhibitor (human))

Angioedemas, Hereditary

Marketing Authorisation Holder: Takeda Manufacturing Austria AG

EMA Authorisation: 15/06/2011

INN: C1 inhibitor (human)

Indication

Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cinryze — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.